Abstract
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.
| Original language | English |
|---|---|
| Journal | JDDG - Journal of the German Society of Dermatology |
| Volume | 9 |
| Issue number | SUPPL. 6 |
| DOIs | |
| State | Published - Oct 1 2011 |
Fingerprint
Keywords
- alopecia
- androgenetic
- Guideline
- hair loss
- Therapy
ASJC Scopus subject areas
- Dermatology
Cite this
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. / Blumeyer, Anja; Tosti, Antonella; Messenger, Andrew; Reygagne, Pascal; Del Marmol, Veronique; Spuls, Phyllis I.; Trakatelli, Myrto; Finner, Andreas; Kiesewetter, Franklin; Trüeb, Ralph; Rzany, Berthold; Blume-Peytavi, Ulrike.
In: JDDG - Journal of the German Society of Dermatology, Vol. 9, No. SUPPL. 6, 01.10.2011.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men
AU - Blumeyer, Anja
AU - Tosti, Antonella
AU - Messenger, Andrew
AU - Reygagne, Pascal
AU - Del Marmol, Veronique
AU - Spuls, Phyllis I.
AU - Trakatelli, Myrto
AU - Finner, Andreas
AU - Kiesewetter, Franklin
AU - Trüeb, Ralph
AU - Rzany, Berthold
AU - Blume-Peytavi, Ulrike
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.
AB - Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.
KW - alopecia
KW - androgenetic
KW - Guideline
KW - hair loss
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=80053986319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053986319&partnerID=8YFLogxK
U2 - 10.1111/j.1610-0379.2011.07802.x
DO - 10.1111/j.1610-0379.2011.07802.x
M3 - Article
C2 - 21980982
AN - SCOPUS:80053986319
VL - 9
JO - JDDG - Journal of the German Society of Dermatology
JF - JDDG - Journal of the German Society of Dermatology
SN - 1610-0379
IS - SUPPL. 6
ER -